Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vivesto AB ( (SE:VIVE) ) has provided an update.
Vivesto AB’s extraordinary general meeting on 22 December 2025 approved a major rights issue of up to 538,043,455 new shares at SEK 0.10 per share, with preferential subscription rights for existing shareholders, requiring amendments to the company’s articles of association to expand the limits for share capital and number of shares. Shareholders also backed a top guarantee arrangement under which Arwidsro Investment AB will guarantee up to SEK 15 million of any unsubscribed portion of the rights issue and authorised the board to issue additional shares as guarantee commission to underwriters, moves that collectively aim to secure Vivesto’s funding base and strengthen its financial position as it advances its oncology pipeline.
More about Vivesto AB
Vivesto AB is a Swedish drug development company focused on creating new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. Its project portfolio includes Cantrixil, under development for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), currently being evaluated in clinical trials in dogs with splenic hemangiosarcoma and in a dose‑finding study in cats with solid tumors. Vivesto’s shares are listed on Nasdaq Stockholm under the ticker VIVE.
YTD Price Performance: -54.14%
Average Trading Volume: 849,629
Technical Sentiment Signal: Sell
Current Market Cap: SEK71.88M
See more insights into VIVE stock on TipRanks’ Stock Analysis page.